Home > Publications database > Glycan-directed SARS-CoV-2 inhibition by leek extract and lectins with insights into the mode-of-action of Concanavalin A > print

001     288987
005     20250825133607.0
024 7 _ |a 10.1016/j.antiviral.2024.105856
|2 doi
024 7 _ |a 0166-3542
|2 ISSN
024 7 _ |a 1872-9096
|2 ISSN
024 7 _ |a altmetric:160425078
|2 altmetric
024 7 _ |a pmid:38447646
|2 pmid
037 _ _ |a DKFZ-2024-00534
082 _ _ |a 610
100 1 _ |a Klevanski, Maja
|0 0000-0002-4041-6102
|b 0
245 _ _ |a Glycan-directed SARS-CoV-2 inhibition by leek extract and lectins with insights into the mode-of-action of Concanavalin A
260 _ _ |a Amsterdam [u.a.]
|c 2024
|b Elsevier Science
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1713534806_15505
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #LA:F170# /NEU/#LA:D430# / 2024 May;225:105856
536 _ _ |a 314 - Immunologie und Krebs (POF4-314)
|0 G:(DE-HGF)POF4-314
|c POF4-314
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, Journals: inrepo02.dkfz.de
700 1 _ |a Kim, Heeyoung
|b 1
700 1 _ |a Heilemann, Mike
|b 2
700 1 _ |a Kuner, Thomas
|b 3
700 1 _ |a Bartenschlager, Ralf
|0 P:(DE-He78)1d3968d2f0ff3eae55f6b2ea4c474387
|b 4
|e Last author
|u dkfz
773 _ _ |a 10.1016/j.antiviral.2024.105856
|g Vol. 225, p. 105856 -
|0 PERI:(DE-600)1495861-2
|p 105856
|t Antiviral research
|v 225
|y 2024
|x 0166-3542
856 4 _ |u https://inrepo02.dkfz.de/record/288987/files/1-s2.0-S0166354224000640-main.pdf
856 4 _ |u https://inrepo02.dkfz.de/record/288987/files/1-s2.0-S0166354224000640-main.pdf?subformat=pdfa
|x pdfa
909 C O |p VDB
|o oai:inrepo02.dkfz.de:288987
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)1d3968d2f0ff3eae55f6b2ea4c474387
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-314
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Immunologie und Krebs
|x 0
914 1 _ |y 2024
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2023-08-19
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ANTIVIR RES : 2022
|d 2023-08-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-08-19
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-08-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-08-19
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-08-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-08-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-08-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-08-19
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b ANTIVIR RES : 2022
|d 2023-08-19
920 2 _ |0 I:(DE-He78)F170-20160331
|k F170
|l Virus-assoziierte Karzinogenese
|x 0
920 1 _ |0 I:(DE-He78)F170-20160331
|k F170
|l Virus-assoziierte Karzinogenese
|x 0
920 1 _ |0 I:(DE-He78)D430-20160331
|k D430
|l Virus-assoziierte Karzinogenese
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)F170-20160331
980 _ _ |a I:(DE-He78)D430-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21